Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features.

@article{Bowen2007MethylprednisolonerituximabIA,
  title={Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features.},
  author={Deborah A Bowen and Timothy G. Call and Greg Jenkins and Clive S Zent and Susan M. Schwager and Daniel L Van Dyke and Diane F. Jelinek and Neil E Kay and Tait D Shanafelt},
  journal={Leukemia & lymphoma},
  year={2007},
  volume={48 12},
  pages={2412-7}
}
Chronic lymphocytic leukemia (CLL) patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond to conventional treatments and have a shorter survival. Studies suggest that high-dose methylprednisolone (HDMP) has activity in such patients and combining HDMP with rituximab may enhance efficacy. We identified 37 patients with CLL treated with the HDMP-rituximab who had follow-up at Mayo Clinic. Nine of 27 (33%) had deletion of 17p13.1 and six of 27 (22%) had… CONTINUE READING

From This Paper

Topics from this paper.
41 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Similar Papers

Loading similar papers…